KRAS G12D
Clinical trials for KRAS G12D explained in plain language.
Never miss a new study
Get alerted when new KRAS G12D trials appear
Sign up with your email to follow new studies for KRAS G12D, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New immunotherapy option for High-Risk pancreatic cancer patients
Disease control AVAILABLEThis expanded access program offers ELI-002 7P, an immunotherapy, to pancreatic cancer patients with specific KRAS or NRAS gene mutations who have had their tumor removed but are at high risk of the cancer coming back. The treatment aims to stimulate the immune system to target a…
Matched conditions: KRAS G12D
Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated Jun 16, 2026 23:38 UTC
-
New pill targets hard-to-treat cancers with KRAS and BRAF mutations
Disease control Recruiting nowThis study tests an experimental oral drug, S241656, in people with advanced cancers (like lung, colon, or pancreatic) that have certain gene changes (KRAS, BRAF, or related). The drug is taken daily in 28-day cycles, either alone or with other cancer treatments. The goal is to f…
Matched conditions: KRAS G12D
Phase: PHASE1, PHASE2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
New pill targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called BBO-11818 in people with advanced cancers that have a KRAS mutation, including lung, pancreatic, and colorectal cancers. The main goals are to check safety and find the best dose, while also seeing if the drug can shrink tumors. Abou…
Matched conditions: KRAS G12D
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated Jun 08, 2026 13:11 UTC
-
New hope for rare blood vessel disorders: targeted drugs enter trial
Disease control Recruiting nowThis study tests two targeted drugs for people with vascular malformations (abnormal blood or lymph vessels). Participants with slow-flow malformations and a specific gene mutation receive alpelisib, while those with fast-flow malformations and another mutation receive mirdametin…
Matched conditions: KRAS G12D
Phase: PHASE2 • Sponsor: Murdoch Childrens Research Institute • Aim: Disease control
Last updated May 19, 2026 12:00 UTC